survival_3year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365*3

master_3year <- master %>% filter(time_to_cre<=365*3,survival_3year==1) 

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_3year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 143,796 -0.90 -1.0, -0.76
1 CI = Confidence Interval

survival_3year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365

master_3year <- master %>% filter(time_to_cre<=365,survival_3year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_3year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 66,956 -6.9 -7.4, -6.3
1 CI = Confidence Interval

Table 1 survival_3year

Overall
(N=2624)
Race
Asian 60 (2.3%)
Black 60 (2.3%)
Other/Unknown 101 (3.8%)
White 2403 (91.6%)
Ethnic_Group
Hispanic 15 (0.6%)
Non_hispanic 2432 (92.7%)
Other 177 (6.7%)
male
0 1222 (46.6%)
1 1402 (53.4%)
diu
0 1254 (47.8%)
1 1370 (52.2%)
ace_arb
0 1378 (52.5%)
1 1246 (47.5%)
esrd_kt
0 2480 (94.5%)
1 144 (5.5%)
dm
0 2271 (86.5%)
1 353 (13.5%)
htn
0 1011 (38.5%)
1 1613 (61.5%)
ppi
0 715 (27.2%)
1 1909 (72.8%)
steroids
0 615 (23.4%)
1 2009 (76.6%)
smoking
0 1222 (46.6%)
1 1402 (53.4%)
cad
0 2050 (78.1%)
1 574 (21.9%)
ICI_Name_clean
Atezolizumab 152 (5.8%)
Avelumab 70 (2.7%)
Cemiplimab 42 (1.6%)
Dostarlimab 0 (0%)
Durvalumab 146 (5.6%)
Ipilimumab 62 (2.4%)
Ipilimumab + Nivolumab 337 (12.8%)
Ipilimumab + Pembrolizumab 1 (0.0%)
Nivolumab 543 (20.7%)
Nivolumab + Relatlimab 1 (0.0%)
Pembrolizumab 1270 (48.4%)
ckd_stage_baseline
Stage 1 1126 (42.9%)
Stage 2 1146 (43.7%)
Stage 3a 263 (10.0%)
Stage 3b 77 (2.9%)
Stage 4 12 (0.5%)
ckd_stage_median
Stage 1 1196 (45.6%)
Stage 2 1123 (42.8%)
Stage 3a 224 (8.5%)
Stage 3b 70 (2.7%)
Stage 4 10 (0.4%)
Stage 5 (Kidney Failure) 1 (0.0%)
age_baseline
Mean (SD) 63.1 (12.7)
Median [Min, Max] 64.7 [8.55, 94.1]
pre_MALBCRE_365days
Mean (SD) 123 (333)
Median [Min, Max] 23.0 [2.60, 2350]
Missing 2543 (96.9%)
pre_CRE_180days
Mean (SD) 0.926 (0.281)
Median [Min, Max] 0.880 [0.300, 2.75]
pre_HGB_180days
Mean (SD) 12.8 (1.77)
Median [Min, Max] 13.0 [6.40, 17.8]
pre_ALB_180days
Mean (SD) 4.11 (0.393)
Median [Min, Max] 4.20 [1.60, 5.40]
Missing 4 (0.2%)
pre_PLT_180days
Mean (SD) 251 (95.5)
Median [Min, Max] 235 [9.00, 1380]
creatinine_median_365
Mean (SD) 0.915 (0.285)
Median [Min, Max] 0.868 [0.360, 4.59]
eGFR_cre_baseline
Mean (SD) 83.9 (20.0)
Median [Min, Max] 86.3 [19.5, 154]
eGFR_cre_median
Mean (SD) 85.0 (19.4)
Median [Min, Max] 87.7 [12.4, 158]
cre_doubling_3year
0 2406 (91.7%)
1 218 (8.3%)

survival_4year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365*4

master_4year <- master %>% filter(time_to_cre<=365*4,survival_4year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_4year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 112,814 -0.78 -0.90, -0.66
1 CI = Confidence Interval

survival_4year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365

master_4year <- master %>% filter(time_to_cre<=365,survival_4year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_4year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 45,098 -7.2 -7.8, -6.5
1 CI = Confidence Interval

Table 1 survival_4year

Overall
(N=1745)
Race
Asian 38 (2.2%)
Black 28 (1.6%)
Other/Unknown 58 (3.3%)
White 1621 (92.9%)
Ethnic_Group
Hispanic 9 (0.5%)
Non_hispanic 1616 (92.6%)
Other 120 (6.9%)
male
0 798 (45.7%)
1 947 (54.3%)
diu
0 847 (48.5%)
1 898 (51.5%)
ace_arb
0 917 (52.6%)
1 828 (47.4%)
esrd_kt
0 1653 (94.7%)
1 92 (5.3%)
dm
0 1518 (87.0%)
1 227 (13.0%)
htn
0 671 (38.5%)
1 1074 (61.5%)
ppi
0 444 (25.4%)
1 1301 (74.6%)
steroids
0 392 (22.5%)
1 1353 (77.5%)
smoking
0 831 (47.6%)
1 914 (52.4%)
cad
0 1375 (78.8%)
1 370 (21.2%)
ICI_Name_clean
Atezolizumab 111 (6.4%)
Avelumab 46 (2.6%)
Cemiplimab 16 (0.9%)
Dostarlimab 0 (0%)
Durvalumab 83 (4.8%)
Ipilimumab 40 (2.3%)
Ipilimumab + Nivolumab 214 (12.3%)
Ipilimumab + Pembrolizumab 1 (0.1%)
Nivolumab 395 (22.6%)
Nivolumab + Relatlimab 1 (0.1%)
Pembrolizumab 838 (48.0%)
ckd_stage_baseline
Stage 1 762 (43.7%)
Stage 2 756 (43.3%)
Stage 3a 168 (9.6%)
Stage 3b 52 (3.0%)
Stage 4 7 (0.4%)
ckd_stage_median
Stage 1 802 (46.0%)
Stage 2 747 (42.8%)
Stage 3a 139 (8.0%)
Stage 3b 49 (2.8%)
Stage 4 7 (0.4%)
Stage 5 (Kidney Failure) 1 (0.1%)
age_baseline
Mean (SD) 62.4 (12.6)
Median [Min, Max] 63.9 [18.4, 94.1]
pre_MALBCRE_365days
Mean (SD) 151 (398)
Median [Min, Max] 21.1 [2.60, 2350]
Missing 1690 (96.8%)
pre_CRE_180days
Mean (SD) 0.931 (0.285)
Median [Min, Max] 0.880 [0.300, 2.75]
pre_HGB_180days
Mean (SD) 12.9 (1.72)
Median [Min, Max] 13.1 [7.20, 17.6]
pre_ALB_180days
Mean (SD) 4.12 (0.384)
Median [Min, Max] 4.20 [1.60, 5.40]
Missing 2 (0.1%)
pre_PLT_180days
Mean (SD) 249 (89.3)
Median [Min, Max] 235 [50.0, 917]
creatinine_median_365
Mean (SD) 0.918 (0.289)
Median [Min, Max] 0.870 [0.360, 4.59]
eGFR_cre_baseline
Mean (SD) 84.1 (20.0)
Median [Min, Max] 86.8 [19.5, 143]
eGFR_cre_median
Mean (SD) 85.4 (19.3)
Median [Min, Max] 88.1 [12.4, 158]
cre_doubling_4year
0 1584 (90.8%)
1 161 (9.2%)

survival_5year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365*5

master_5year <- master %>% filter(time_to_cre<=365*5,survival_5year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_5year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 79,456 -0.56 -0.68, -0.45
1 CI = Confidence Interval

survival_5year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365

master_5year <- master %>% filter(time_to_cre<=365,survival_5year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_5year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 29,759 -7.8 -8.7, -7.0
1 CI = Confidence Interval

Table 1 survival_5year

Overall
(N=1088)
Race
Asian 22 (2.0%)
Black 19 (1.7%)
Other/Unknown 38 (3.5%)
White 1009 (92.7%)
Ethnic_Group
Hispanic 6 (0.6%)
Non_hispanic 1005 (92.4%)
Other 77 (7.1%)
male
0 497 (45.7%)
1 591 (54.3%)
diu
0 535 (49.2%)
1 553 (50.8%)
ace_arb
0 569 (52.3%)
1 519 (47.7%)
esrd_kt
0 1039 (95.5%)
1 49 (4.5%)
dm
0 959 (88.1%)
1 129 (11.9%)
htn
0 410 (37.7%)
1 678 (62.3%)
ppi
0 261 (24.0%)
1 827 (76.0%)
steroids
0 241 (22.2%)
1 847 (77.8%)
smoking
0 529 (48.6%)
1 559 (51.4%)
cad
0 868 (79.8%)
1 220 (20.2%)
ICI_Name_clean
Atezolizumab 74 (6.8%)
Avelumab 32 (2.9%)
Cemiplimab 2 (0.2%)
Dostarlimab 0 (0%)
Durvalumab 34 (3.1%)
Ipilimumab 30 (2.8%)
Ipilimumab + Nivolumab 101 (9.3%)
Ipilimumab + Pembrolizumab 1 (0.1%)
Nivolumab 304 (27.9%)
Nivolumab + Relatlimab 1 (0.1%)
Pembrolizumab 509 (46.8%)
ckd_stage_baseline
Stage 1 521 (47.9%)
Stage 2 442 (40.6%)
Stage 3a 95 (8.7%)
Stage 3b 26 (2.4%)
Stage 4 4 (0.4%)
ckd_stage_median
Stage 1 540 (49.6%)
Stage 2 437 (40.2%)
Stage 3a 82 (7.5%)
Stage 3b 23 (2.1%)
Stage 4 5 (0.5%)
Stage 5 (Kidney Failure) 1 (0.1%)
age_baseline
Mean (SD) 61.4 (12.5)
Median [Min, Max] 62.6 [18.4, 90.7]
pre_MALBCRE_365days
Mean (SD) 85.7 (225)
Median [Min, Max] 18.6 [2.60, 1130]
Missing 1059 (97.3%)
pre_CRE_180days
Mean (SD) 0.914 (0.278)
Median [Min, Max] 0.860 [0.300, 2.75]
pre_HGB_180days
Mean (SD) 13.0 (1.70)
Median [Min, Max] 13.2 [7.20, 17.1]
pre_ALB_180days
Mean (SD) 4.11 (0.386)
Median [Min, Max] 4.10 [1.60, 5.20]
Missing 2 (0.2%)
pre_PLT_180days
Mean (SD) 248 (92.7)
Median [Min, Max] 234 [50.0, 917]
creatinine_median_365
Mean (SD) 0.908 (0.297)
Median [Min, Max] 0.860 [0.360, 4.59]
eGFR_cre_baseline
Mean (SD) 85.9 (19.8)
Median [Min, Max] 88.8 [19.5, 143]
eGFR_cre_median
Mean (SD) 86.8 (19.3)
Median [Min, Max] 89.8 [12.4, 158]
cre_doubling_5year
0 985 (90.5%)
1 103 (9.5%)

survival_6year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365*6

master_6year <- master %>% filter(time_to_cre<=365*6,survival_6year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_6year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 54,554 -0.45 -0.56, -0.34
1 CI = Confidence Interval

survival_6year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365

master_6year <- master %>% filter(time_to_cre<=365,survival_6year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_6year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 18,644 -6.2 -7.2, -5.1
1 CI = Confidence Interval

Table 1 survival_6year

Overall
(N=664)
Race
Asian 11 (1.7%)
Black 16 (2.4%)
Other/Unknown 20 (3.0%)
White 617 (92.9%)
Ethnic_Group
Hispanic 5 (0.8%)
Non_hispanic 606 (91.3%)
Other 53 (8.0%)
male
0 314 (47.3%)
1 350 (52.7%)
diu
0 338 (50.9%)
1 326 (49.1%)
ace_arb
0 347 (52.3%)
1 317 (47.7%)
esrd_kt
0 635 (95.6%)
1 29 (4.4%)
dm
0 582 (87.7%)
1 82 (12.3%)
htn
0 242 (36.4%)
1 422 (63.6%)
ppi
0 141 (21.2%)
1 523 (78.8%)
steroids
0 142 (21.4%)
1 522 (78.6%)
smoking
0 329 (49.5%)
1 335 (50.5%)
cad
0 536 (80.7%)
1 128 (19.3%)
ICI_Name_clean
Atezolizumab 46 (6.9%)
Avelumab 17 (2.6%)
Cemiplimab 0 (0%)
Dostarlimab 0 (0%)
Durvalumab 14 (2.1%)
Ipilimumab 28 (4.2%)
Ipilimumab + Nivolumab 63 (9.5%)
Ipilimumab + Pembrolizumab 0 (0%)
Nivolumab 178 (26.8%)
Nivolumab + Relatlimab 1 (0.2%)
Pembrolizumab 317 (47.7%)
ckd_stage_baseline
Stage 1 330 (49.7%)
Stage 2 259 (39.0%)
Stage 3a 56 (8.4%)
Stage 3b 16 (2.4%)
Stage 4 3 (0.5%)
ckd_stage_median
Stage 1 341 (51.4%)
Stage 2 264 (39.8%)
Stage 3a 39 (5.9%)
Stage 3b 16 (2.4%)
Stage 4 3 (0.5%)
Stage 5 (Kidney Failure) 1 (0.2%)
age_baseline
Mean (SD) 61.1 (12.3)
Median [Min, Max] 62.3 [18.4, 87.7]
pre_MALBCRE_365days
Mean (SD) 86.4 (262)
Median [Min, Max] 18.3 [2.60, 1130]
Missing 646 (97.3%)
pre_CRE_180days
Mean (SD) 0.912 (0.283)
Median [Min, Max] 0.865 [0.300, 2.75]
pre_HGB_180days
Mean (SD) 13.0 (1.66)
Median [Min, Max] 13.2 [7.30, 16.8]
pre_ALB_180days
Mean (SD) 4.10 (0.400)
Median [Min, Max] 4.10 [1.60, 5.00]
Missing 2 (0.3%)
pre_PLT_180days
Mean (SD) 249 (91.0)
Median [Min, Max] 234 [62.0, 917]
creatinine_median_365
Mean (SD) 0.903 (0.304)
Median [Min, Max] 0.860 [0.405, 4.59]
eGFR_cre_baseline
Mean (SD) 86.0 (19.9)
Median [Min, Max] 89.8 [19.5, 143]
eGFR_cre_median
Mean (SD) 87.1 (19.2)
Median [Min, Max] 90.8 [12.4, 158]
cre_doubling_6year
0 602 (90.7%)
1 62 (9.3%)

survival_7year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365*7

master_7year <- master %>% filter(time_to_cre<=365*7,survival_7year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_7year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 32,639 -0.40 -0.52, -0.28
1 CI = Confidence Interval

survival_7year cohort Model post_egfr ~ time_to_cre_year : time_to_cre<=365

master_7year <- master %>% filter(time_to_cre<=365,survival_7year==1)

model <- lmer(post_egfr ~ time_to_cre_year + (1 | EMPI), data = master_7year)
model %>% tbl_regression( exponentiate = FALSE) %>% add_n()
Characteristic N Beta 95% CI1
time_to_cre_year 10,617 -4.5 -5.9, -3.2
1 CI = Confidence Interval

Table 1 survival_7year

Overall
(N=368)
Race
Asian 5 (1.4%)
Black 10 (2.7%)
Other/Unknown 9 (2.4%)
White 344 (93.5%)
Ethnic_Group
Hispanic 3 (0.8%)
Non_hispanic 330 (89.7%)
Other 35 (9.5%)
male
0 160 (43.5%)
1 208 (56.5%)
diu
0 186 (50.5%)
1 182 (49.5%)
ace_arb
0 188 (51.1%)
1 180 (48.9%)
esrd_kt
0 356 (96.7%)
1 12 (3.3%)
dm
0 323 (87.8%)
1 45 (12.2%)
htn
0 127 (34.5%)
1 241 (65.5%)
ppi
0 77 (20.9%)
1 291 (79.1%)
steroids
0 84 (22.8%)
1 284 (77.2%)
smoking
0 184 (50.0%)
1 184 (50.0%)
cad
0 302 (82.1%)
1 66 (17.9%)
ICI_Name_clean
Atezolizumab 29 (7.9%)
Avelumab 12 (3.3%)
Cemiplimab 0 (0%)
Dostarlimab 0 (0%)
Durvalumab 4 (1.1%)
Ipilimumab 18 (4.9%)
Ipilimumab + Nivolumab 43 (11.7%)
Ipilimumab + Pembrolizumab 0 (0%)
Nivolumab 88 (23.9%)
Nivolumab + Relatlimab 0 (0%)
Pembrolizumab 174 (47.3%)
ckd_stage_baseline
Stage 1 187 (50.8%)
Stage 2 135 (36.7%)
Stage 3a 37 (10.1%)
Stage 3b 8 (2.2%)
Stage 4 1 (0.3%)
ckd_stage_median
Stage 1 197 (53.5%)
Stage 2 132 (35.9%)
Stage 3a 27 (7.3%)
Stage 3b 11 (3.0%)
Stage 4 1 (0.3%)
Stage 5 (Kidney Failure) 0 (0%)
age_baseline
Mean (SD) 60.9 (12.0)
Median [Min, Max] 62.3 [18.4, 85.8]
pre_MALBCRE_365days
Mean (SD) 108 (309)
Median [Min, Max] 17.4 [2.60, 1130]
Missing 355 (96.5%)
pre_CRE_180days
Mean (SD) 0.919 (0.267)
Median [Min, Max] 0.880 [0.310, 1.95]
pre_HGB_180days
Mean (SD) 12.9 (1.73)
Median [Min, Max] 13.2 [7.30, 16.7]
pre_ALB_180days
Mean (SD) 4.11 (0.411)
Median [Min, Max] 4.10 [1.60, 5.00]
Missing 1 (0.3%)
pre_PLT_180days
Mean (SD) 248 (92.8)
Median [Min, Max] 236 [75.0, 917]
creatinine_median_365
Mean (SD) 0.907 (0.252)
Median [Min, Max] 0.870 [0.420, 2.02]
eGFR_cre_baseline
Mean (SD) 86.0 (19.9)
Median [Min, Max] 90.3 [28.4, 130]
eGFR_cre_median
Mean (SD) 87.0 (19.4)
Median [Min, Max] 91.7 [29.7, 131]
cre_doubling_7year
0 326 (88.6%)
1 42 (11.4%)